You are here: Home » International » News » Others
Business Standard

Brazil to receive China's Sinovac COVID-19 vaccine, eyes Pfizer candidate

Federal health officials met with Pfizer representatives on as Brazil seeks to secure vaccine supplies

Topics
Coronavirus Vaccine | Pfizer | China

Reuters  |  BRASILIA 

Federal health officials met with Pfizer representatives on Tuesday as Brazil seeks to secure vaccine supplies. Photo: Reuters
Federal health officials met with Pfizer representatives on Tuesday as Brazil seeks to secure vaccine supplies. Photo: Reuters

By Ricardo Brito and Anthony Boadle

BRASILIA (Reuters) - Brazil's Sao Paulo state is set to begin importing the first of 46 million doses of China's Sinovac vaccine against COVID-19 this week, while the federal government takes a more cautious approach with a vaccine developed by Inc.

Federal health officials met with representatives on Tuesday as seeks to secure vaccine supplies. The Health Ministry said in a statement that it would buy the vaccine, currently in Phase 3 trials, if it was proven safe and was registered with health authority Anvisa.

As it draws up immunization plans, the ministry will also meet this week with Johnson & Johnson, India's Bharat Biotech and the makers of Russia's Sputnik V vaccine.

has the third-highest coronavirus case count in the world, leading many pharmaceutical companies to do trials of their vaccines in South America's largest country.

State health authorities have taken a more aggressive stance than their federal counterparts on securing vaccine supplies.

The director of Sao Paulo state's Butantan Institute biomedical center, Dimas Covas, told a congressional hearing on Tuesday that Butantan expected to have 46 million doses of Sinovac ready in January to be used if approved by Brazil's health regulator Anvisa.

Butantan is organizing the Phase 3 trials of the vaccine in Brazil, with Covas saying preliminary results indicate it has an excellent safety profile.

Covas said 10,000 volunteers had already received about 19,000 shots of the two-dose vaccine, and 2,000 other people had still to be included in the trials.

Anvisa suspended the trials for a day and a half last week after the death of a volunteer, which police reported as a suicide and Butantan said had no relation to the vaccine.

The temporary halt had no affect on the clinical trials, Covas said, adding that Butantan had a "very good understanding" with Anvisa.

Butantan and Anvisa have sent experts to where they are in a two-week quarantine before they can visit vaccine facilities, they said.

 

(Reporting by Anthony Boadle, Ricardo Brito and Maria Carolina Marcello; Writing by Jake Spring; Editing by Sonya Hepinstall and Peter Cooney)

(Only the headline and picture of this report may have been reworked by the Business Standard staff; the rest of the content is auto-generated from a syndicated feed.)

Dear Reader,


Business Standard has always strived hard to provide up-to-date information and commentary on developments that are of interest to you and have wider political and economic implications for the country and the world. Your encouragement and constant feedback on how to improve our offering have only made our resolve and commitment to these ideals stronger. Even during these difficult times arising out of Covid-19, we continue to remain committed to keeping you informed and updated with credible news, authoritative views and incisive commentary on topical issues of relevance.
We, however, have a request.

As we battle the economic impact of the pandemic, we need your support even more, so that we can continue to offer you more quality content. Our subscription model has seen an encouraging response from many of you, who have subscribed to our online content. More subscription to our online content can only help us achieve the goals of offering you even better and more relevant content. We believe in free, fair and credible journalism. Your support through more subscriptions can help us practise the journalism to which we are committed.

Support quality journalism and subscribe to Business Standard.

Digital Editor

First Published: Wed, November 18 2020. 08:12 IST
RECOMMENDED FOR YOU
.